For pancreatic cancer that can be removed completely and shows no evidence of spread, surgery first followed by chemotherapy is a standard approach. When the tumor is borderline resectable, usually because of its relationship to nearby blood vessels, chemotherapy first is generally preferred, followed by a review to see whether surgery is feasible. Locally advanced cancer usually starts with chemotherapy, with surgery reconsidered in selected cases. When the cancer has spread to distant organs, treatment usually centres on medicines and symptom control. [1, 2]
By Dr Raman Narang, Consultant Medical & Hemato-Oncologist, New Delhi
One of the first questions families ask after a pancreatic cancer diagnosis is, “If surgery is possible, why wait?” The answer depends on what the scans show, how likely surgery is to remove the cancer completely, and whether starting with chemotherapy would help the team judge how the disease behaves. If you are seeking pancreatic cancer treatment in Delhi, ask for the tumor’s resectability category as well as its stage. That category helps explain why the team recommends surgery or chemotherapy first.
This page focuses on pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. Pancreatic neuroendocrine tumors follow a different treatment pathway.
1. What are the symptoms of pancreatic cancer, and how is it diagnosed?
Early pancreatic cancer may cause few symptoms. Possible signs include yellowing of the eyes or skin, dark urine, pale stools, persistent upper abdominal or back pain, unexplained weight loss, and loss of appetite. A tumor in the head of the pancreas can block the bile duct and cause jaundice. New jaundice warrants prompt assessment. Jaundice with fever or chills requires urgent medical care. [2, 3]
A pancreas-protocol contrast CT helps the team see the tumor, assess its relationship to major blood vessels, and look for spread. MRI can help clarify uncertain findings, such as a small liver lesion that could change the recommendation about surgery. [1–3]
A biopsy is generally needed before starting chemotherapy. It is often obtained using endoscopic ultrasound, which allows the doctor to sample the tumor through the stomach or duodenum. In selected patients with a typical scan and a clearly resectable tumor, the team may proceed directly to surgery without a preoperative biopsy. [1–3]
The blood test CA 19-9 can support assessment and help track treatment response in some patients. A blocked bile duct can raise it, and some patients produce little or none. The team interprets the result alongside bilirubin, imaging, and the clinical picture. [1, 2]
2. What determines whether surgery is done first or after chemotherapy?
The team reviews three questions together. Can the tumor be removed completely? Is there evidence that it has spread? Is the patient fit enough for the planned operation and systemic treatment? A pancreatic surgeon, radiologist, and medical oncologist review the original images because the details of blood vessel involvement can change the sequence. [1, 2]
| What the team assesses | How it can change the plan |
|---|---|
| Contact with major veins or arteries | The team checks which vessel is involved, how much of it is in contact with the tumor, and whether a section of vein can be safely removed and reconstructed if necessary. |
| Likelihood of a clear surgical margin | If operating now carries a high risk of leaving microscopic cancer at the cut edge, chemotherapy first may offer a better route to a complete removal. |
| Evidence or suspicion of distant spread | A suspicious liver lesion or other uncertain finding may need more evaluation before a major operation. Confirmed distant spread usually leads to systemic treatment. |
| Signs of higher-risk disease | A markedly raised CA 19-9 after accounting for bile duct obstruction, or concerning findings on imaging, can prompt further staging and a discussion about chemotherapy first even when surgery appears technically possible. |
| Fitness, nutrition, and bile duct obstruction | Frailty, substantial weight loss, other illnesses, or complications from jaundice can affect which treatment is safe to start and what needs attention beforehand. |
Tumor size is only one part of the decision. A smaller tumor in close contact with a major artery may be harder to remove than a larger tumor with a clear surgical plane. The word resectable describes whether complete removal appears feasible after reviewing the anatomy and the extent of disease. [1, 2]
3. How is early or clearly resectable pancreatic cancer treated?
When imaging shows no distant spread and the team expects a complete removal, upfront surgery followed by postoperative chemotherapy is a standard pathway for a patient fit enough for the operation. The operation depends on where the tumor sits. A Whipple procedure is commonly used for tumors in the head of the pancreas. A distal pancreatectomy may be used for tumors in the body or tail. [1, 2]
The final pathology shows whether cancer was found at a surgical margin or in nearby lymph nodes. Adjuvant chemotherapy, given after surgery, aims to reduce the risk of recurrence by treating microscopic disease that may remain elsewhere in the body. Modified FOLFIRINOX is one option for suitable patients who recover well enough after surgery. Other regimens may be more appropriate depending on recovery and overall health. [1, 2]
For some patients with technically resectable disease, the team may discuss chemotherapy first because the scans or other findings raise concern about the risk of early spread. The reasons should be specific to the case. Ask what finding makes chemotherapy first worth considering and when the team would reassess for surgery. [1, 2]
4. How are borderline resectable and locally advanced pancreatic cancers treated?
Borderline resectable pancreatic cancer has no identified distant spread, but its relationship to nearby blood vessels makes a complete operation uncertain. Chemotherapy first is generally preferred. It treats possible microscopic disease early and gives the team time to see whether the cancer remains confined before undertaking a major operation. [1, 2]
After chemotherapy, the team reviews repeat imaging, any informative change in CA 19-9, symptoms, physical fitness, and whether a complete operation is feasible. The tumor may still appear to touch a vessel on the scan because treatment-related scarring can resemble residual cancer. In selected borderline cases, surgery can still be considered even when the scan shows little shrinkage. New distant spread usually changes the plan away from surgery. [1, 2]
Locally advanced pancreatic cancer has no identified distant metastases, but the extent of local involvement makes complete removal unlikely at diagnosis. Chemotherapy is usually the first treatment. After reassessment, a specialist pancreatic surgery team may reconsider an operation in selected patients. Radiation or chemoradiation may also be discussed in selected cases to help control disease in the pancreas or manage local symptoms. [1, 2]
5. How is metastatic pancreatic cancer treated?
When pancreatic cancer has spread to distant organs, such as the liver, lungs, or abdominal lining, systemic treatment is usually the main approach. The goals are to control the disease, relieve symptoms, and help patients live longer where possible. Surgery to remove the pancreatic tumor is generally outside the standard treatment pathway in this setting. [1, 2]
Chemotherapy options include FOLFIRINOX, NALIRIFOX, or gemcitabine plus nab-paclitaxel for suitable patients. The choice depends on overall fitness, liver function, existing nerve symptoms, and treatment priorities. Some patients benefit from a less intensive regimen or from prioritising symptom-directed care. [1, 2]
Inherited genetic testing and tumor biomarker testing can identify options for a small group of patients. For example, an inherited BRCA1 or BRCA2 alteration can affect chemotherapy choices and may make maintenance targeted therapy relevant in selected metastatic cases after disease control on first-line platinum chemotherapy. Rare findings such as MSI-high or mismatch repair deficiency can make immunotherapy an option in the appropriate setting. The exact result, treatment history, and locally applicable prescribing indication guide use. [1, 2]
Supportive care can start alongside cancer treatment. It can include pain relief, nutrition support, management of bile duct obstruction, and pancreatic enzyme replacement when poor digestion contributes to weight loss or oily stools. [1, 2]
What I look for clinically before recommending surgery or chemotherapy first
I start with the original pancreas-protocol CT images. If the report says “borderline resectable,” I want to know which vessel is involved and what makes a complete removal uncertain. I also look for findings that need clarification before committing to surgery, such as a small indeterminate liver lesion or a CA 19-9 result measured during jaundice. If we recommend chemotherapy first, I explain what we will reassess and what findings would make an operation reasonable.
How the next step is decided
| If the reports show… | The next discussion is about… |
|---|---|
| Clearly resectable disease and the patient is fit for surgery | Upfront surgery, recovery, and postoperative chemotherapy |
| A technically removable tumor with concerning findings | Whether more staging is needed and whether chemotherapy first is appropriate |
| Borderline resectable disease | Biopsy confirmation, chemotherapy first, and a planned reassessment for surgery |
| Locally advanced disease | Systemic treatment and whether later surgery or radiation might be appropriate |
| Distant metastases | Systemic therapy, biomarker testing, and symptom support |
What to bring to a pancreatic cancer consultation in Delhi
- Pancreas-protocol CT, MRI, or other staging reports and the original images.
- Biopsy and pathology reports, if available.
- CA 19-9 and bilirubin results, with dates and whether they were taken before or after bile duct drainage.
- Endoscopic ultrasound, ERCP, and bile duct stent records, if applicable.
- A note of recent weight loss, changes in appetite or stools, pain, and any difficulty eating.
- The proposed treatment plan and details of any chemotherapy already received.
Frequently asked questions
Does contact with a blood vessel rule out surgery?
Some tumors involving a nearby vein can be removed with vein reconstruction. The specific vessel, extent of involvement, and likelihood of a clear margin determine whether surgery is feasible and when to consider it. [1, 2]
Does the tumor have to shrink before surgery can be considered?
Visible shrinkage is one piece of information. The team also looks for new spread, assesses fitness, and reviews whether a complete operation appears possible. Persistent tissue around a vessel can reflect treatment-related scarring. [1, 2]
Why is chemotherapy recommended after the tumor has been removed?
A complete operation removes the visible tumor. Postoperative chemotherapy aims to treat microscopic disease that may remain elsewhere and reduce the chance of recurrence. [1, 2]
Is radiation needed for every pancreatic cancer?
Radiation is used selectively. In locally advanced disease, the team may consider it after initial chemotherapy for local control or to relieve certain symptoms. Its role depends on the clinical situation and treatment goal. [1, 2]
Before choosing a treatment plan, ask your team to explain the resectability category, the finding that determines which treatment comes first, and the result that would change the plan. For patients starting chemotherapy first, it helps to know when the next surgical review is planned.
This page is for general education. Individual treatment decisions require review of your imaging, pathology, symptoms, and overall health by your treating team.
Clinical references
- ESMO. Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Diagnosis, Treatment and Follow-up of Patients with Pancreatic Cancer.
- National Cancer Institute. Pancreatic Cancer Treatment (PDQ), Health Professional Version.
- National Cancer Institute. Pancreatic Cancer Testing and Diagnosis.